Tyrosine: Food supplement or therapeutic agent?

Journal of Nutritional and Environmental Medicine

Volumn 8, Issue 4, 1998, Pages 349-359

  Tyrrell, Henry A ^a   Maher, Timothy J ^b  

^a Tyrrell Pharmaceutical Consultancy   (United Kingdom)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Clinical trial; Depression; Melanin; Parkinson's disease; Patent; Research; Side effects; Stress; Toxicology; Tyrosine

Indexed keywords

ADRENALIN; AMINO ACID; CATECHOLAMINE DERIVATIVE; DOPAMINE; LEVODOPA; MELANIN; NORADRENALIN; THYROXINE; TYROSINE; TYROSINE 3 MONOOXYGENASE;

ADRENAL MEDULLA; ARMY; BRAIN NERVE CELL; COLD; DEPRESSION; DIET SUPPLEMENTATION; DRUG MEGADOSE; DRUG SAFETY; FINANCIAL MANAGEMENT; HUMAN; HYPOXIA; MEDICAL RESEARCH; MELANOGENESIS; NERVE STIMULATION; NOISE; NONHUMAN; NUTRITIONAL DEFICIENCY; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REVIEW; RISK BENEFIT ANALYSIS; STRESS; SYMPATHETIC NERVE CELL; TASK PERFORMANCE; WAKEFULNESS;

EID: 0032406428     PISSN: 13590847     EISSN: None     Source Type: Journal    
DOI: 10.1080/13590849861934     Document Type: Review

References (52)

1. Food and Nutrition Board, National Research Council. Recommended Dietary Allowances, 10th edition. Washington, DC: National Academy Press, 1989.
2. Fernstrom JD, Fernstrom MH. Dietary effects on tyrosine availability and catecholamine synthesis in the central nervous system: possible relevance to the control of protein intake. Proc Nutr Soc 1994; 53: 419-29.
3. Cuche JL, Prinseau J, Selz F, et al., Oral load of tvrosine or L-DOPA and plasma levels of free and sulfoconjugated catecholamines in healthy men. Hypertension 1985; 7: 81-9.
4. Melamed E, Glaeser B, Growdon JH, Wurtman RJ. Plasma tyrosine in normal humans: effects of oral tyrosine and protein-containing meals. J Neural Transm 1980; 47: 299-306.
5. Goldstein M, Lieberman A. The role of regulatory enzymes of catecholamine synthesis in Parkinson's disease. Neurology 1992; 42: 8-12.
6. Nagatsu T, Ichinose H. Molecular biology of catecholamine neurons in relation to Parkinson's disease. Adv Neurol 1996; 69: 147-52.
7. Sved AF. Precursor control of the function of monoamine neurons. In: Wurtman RJ, Wurtman JJ, eds. Nutrition and the Brain, Vol 6, Physiological and Behavioral Effects of Food Constituents. New York: Raven Press 1983; 223-75.
8. Badawy AB, Williams DL. Enhancement of rat brain catccholamine synthesis by administration of small doses of tyrosine and evidence for substrate inhibition of tyrosine hydroxylase activity by large doses of the amino acid. Biochem J 1982; 206: 165-8.
9. Nasrin S, Ichinose H, Hidaka H, Nagatsu T. Recombinant human tyrosine hydroxylase types 1-4 show regulatory kinetic properties for the natural (6R)-tetrahydrobiopterin cofactor. J Biochem 1994; 116: 393-8.
10. Wurtman RJ. Behavioural effects of nutrients. Lancet 1983. i: 1145-7.
11. Lehnert H, Wurtman RJ. Amino acid control of neurotransmitter synthesis and release, physiological and clinical implications. Psychother Psychosom 1993; 60: 18-32.
12. Homykiewicz O. The mechanisms of action of L-DOPA in Parkinson's disease. Life Sci 1974; 15: 1249-59.
13. Tohgi H, Takashi A, Takahashi S, et al. Concentrations of tyrosine, L-dihydroxyphenylalanine, dopamine, and 3-O-methyldopa in the cerebrospinal fluid of Parkinson's disease. Neurosci Lett 1991; 127: 212-4.
14. Mogi M, Harada M, Kiuchi K, et al. Homospecific activity (activity per enzvme protein) of tyrosine hydroxylase increases in Parkinsonian brain. J Neural Transm 1988; 72: 77-81.
15. Growdon JH, Melamed E, Logue M, et al., Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease. Life Sci 1982; 30: 827-32.
16. Growdon JH. Tyrosine treatment in Parkinson disease: clinical effects. Neurology (NY) 1981; 31: 134.
17. Lemoine P, Robelin N, Sebert P, Mouret J. L-Tyrosine: A long term treatment of Parkinson's disease. C R Acad Sci Paris 1989; 309: 43-7.
18. Birkmayer JGD, Vrecko C, Vole D, Birkmayer W. Nicotinamide adenine dinucleotide (NADH) - a new therapeutic approach to Parkinson's disease. Acta Neurol Scand 1993; 87: 32-5.
19. Kuhn W, Muller T, Winkel R, et al. Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis. J Neural Transm 1996; 103: 1187-93.
20. Wallis RA, Panizzon KL, Henry D, Wasterlain CG. Neuroprotection against nitric oxide injury with inhibitors of ADP-ribosylation. Neuroreport 1993, 5: 245-8.
21. Beal MF, Henshaw DR, Jenkins BG, et al. Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Ann Neurol 1994; 36: 882-8.
22. Schulz JB, Henshaw DR, Matthews RT, Beal MF. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp Neurol 1995; 132: 279-83.
23. Maruyama W, Naoi M, Takahashi A, et al. The mechanism of perturbation in monoamine metabolism by L-dopa therapy: in-vivo and in-vitro studies. J Neural Transm 1992; 90: 183-97.
24. Riederer P. L-DOPA competes with tyrosine and tryptophan for human brain uptake. Nutr Metab 1980; 24: 417-23.
25. Melamed E. Biochemical and functional differences between dopamine formed from endogenous tyrosine and exogenous L-dopa in nigrostriatal dopaminergic neurons. Neurochem Int 1992; 20:115S-7S.
26. Brown AS, Gershon S. Dopamine and depression. J Neural Transm Gen Sect 1993; 91: 75-109.
27. Goldberg IK. L-Tyrosine in depression. Lancet 1980; ii: 364.
28. Hoskins JA. L-Tyrosine in depression. Lancet 1980; ii: 597.
29. Gelenberg AJ, Wurtman RJ. L-Tyrosine in depression. Lancet 1980; ii: 863-4.
30. Mouret J, Lemoine P, Minuit MP, Robelin N. L-Tyrosine cures immediate and long term dopamine-dependent depressions. Clinical and polygraphic studies. C R Acad Sci III 1988; 306: 93-8.
31. Moller SB, Maach-Moller B, Olesen M, et al., Tyrosine metabolism in users of oral contraceptives. Life Sci 1995; 56: 687-95.
32. Gelenberg AJ, Wojeik JD, Falk WE, et al. Tyrosine for depression: a double-blind trial. J Affect Disord 1990; 19: 125-32.
33. Felman RS, Meyer JS, Quenzer LF (Editors). Principles of Neuropsychopharmacology. Sunderland, Massachusetts: Sinauer Associates Inc. 1997, p. 843.
34. Prange AJ Jr. Novel uses of thyroid hormones in patients with affective disorders. Thyroid 1996; 6: 537-43.
35. Whybrow PC, Prange AJ Jr. A hypothesis of thyroid-catecholamine-receptor interaction. Its relevance to affective illness. Arch Gen Psychiatry 1981; 38: 106-13.
36. Owasoyo JO, Neri DF, Lamberth JG. Tyrosinc and its potential use as a countermeasure to performance decrement in military sustained operations. Aviat Space Environ Med 1992 (May); 364-9.
37. Banderet LE, Lieberman HR. Treatment with tyrosine, a neurotransmitter precursor, reduces stress in humans. Brain Res Bull 1989; 22: 759-62.
38. Dollins AB, Krock LP, Storm WF, Lieberman HR. Tyrosine decreases physiological stress caused by lower body negative pressure. Aviat Space Environ Med 1990; 61: 491.
39. Deijen JB, Orlebeke JF. Effect of tyrosinc on cognitive function and blood pressure under stress. Brain Res Bull 1994; 33: 319-23.
40. Shurtleff D, Thomas JR, Kowalski K, Harford R. Tyrosine reverses a cold-induced working memory deficit in humans. Pharmacol Biochem Behav 1994; 47: 935-41.
41. Neri DF, Wiegmann D, Stanny RR, et al. The effects of tyrosinc on cognitive performance during extended wakefulness. Aviat Space Environ Med 1995; 66: 313-9.
42. Al-Damlugi S, Ross G, Touzel R, et al. Modulation of the actions of tyrosine by alpha 2-adrenoceptor blockade. Br J Pharmacol 1988; 95: 405-12.
43. Conlay LA, Maher TJ, Wurtman RJ. Tyrosine's pressor effect in hypotensive rats is not mediated by tyramine. Life Sci 1984; 35: 1207-12.
44. Gilchrest BA, Park HY, Eller MS, Yaar M. Mechanisms of ultraviolet light-induced pigmentation. Photochem Photobiol 1996; 63: 1-10.
45. Sober AJ, Wick MM. Levodopa therapy and malignant melanoma. JAMA 1978; 240: 554-5.
46. Kleinhans M, Schmid-Grendelmeier P, Burg G. Levodopa and malignant melanoma - case report and review of the literature. A contribution to causal relationship between levodopa and the development of malignant melanoma. Hautarzt 1996; 47: 432-7.
47. Eisenberg J, Asnis GM, van Praag HM, Vela RM. Effect of tyrosine on attention deficit disorder with hyperactivity. J Clin Psychiatry 1988; 49: 193-5.
48. Elwes RDC, Crewes H, Chesterman LP, et al. Treatment of narcolepsy with L-tyrosine: double-blind placebo-controlled trial. Lancet 1989; 1067-9.
49. Deutsch SI, Rosse RB, Schwanz BL, et al. L-tyrosine pharmacotherapy of schizophrenia: preliminary data. Clin Neuropharmacol 1994; 17: 53-62.
50. Galloway GP, Frederick SL, Thomas S, et al. A historically controlled trial of tyrosine for cocaine dependence. J Psychoactive Drugs 1996; 28: 305-9.
51. Life Sciences Research office. Safety of amino acids used as dietary supplements, July 1992.
52. Anon. ECJ Advocate General defines "essential similarity". Scrip 1998; No 2304, 28 January; p. 4. PJB Publications.